364 related articles for article (PubMed ID: 35484505)
1. The effect of renin-angiotensin-aldosterone system inhibitors on continuous and binary kidney outcomes in subgroups of patients with diabetes: a meta-analysis of randomized clinical trials.
Alsalemi N; Sadowski CA; Elftouh N; Louis M; Kilpatrick K; Houle SKD; Lafrance JP
BMC Nephrol; 2022 Apr; 23(1):161. PubMed ID: 35484505
[TBL] [Abstract][Full Text] [Related]
2. Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality and Renal Outcomes in Patients with Diabetes and Albuminuria: a Systematic Review and Meta-Analysis.
Wang K; Hu J; Luo T; Wang Y; Yang S; Qing H; Cheng Q; Li Q
Kidney Blood Press Res; 2018; 43(3):768-779. PubMed ID: 29794446
[TBL] [Abstract][Full Text] [Related]
3. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis.
Vejakama P; Thakkinstian A; Lertrattananon D; Ingsathit A; Ngarmukos C; Attia J
Diabetologia; 2012 Mar; 55(3):566-78. PubMed ID: 22189484
[TBL] [Abstract][Full Text] [Related]
4. Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention.
Petrykiv SI; Laverman GD; Persson F; Vogt L; Rossing P; de Borst MH; Gansevoort RT; de Zeeuw D; Heerspink HJL
Clin J Am Soc Nephrol; 2017 Nov; 12(11):1804-1813. PubMed ID: 29021336
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy of individual renin-angiotensin system inhibitors on major renal outcomes in diabetic kidney disease: a network meta-analysis.
Cai J; Huang X; Zheng Z; Lin Q; Peng M; Shen D
Nephrol Dial Transplant; 2018 Nov; 33(11):1968-1976. PubMed ID: 29579289
[TBL] [Abstract][Full Text] [Related]
6. Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?
Petrykiv S; Laverman GD; de Zeeuw D; Heerspink HJL
Diabetes Obes Metab; 2018 Jan; 20(1):224-227. PubMed ID: 28685934
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.
Feng Y; Huang R; Kavanagh J; Li L; Zeng X; Li Y; Fu P
Am J Cardiovasc Drugs; 2019 Jun; 19(3):259-286. PubMed ID: 30737754
[TBL] [Abstract][Full Text] [Related]
8. Evidence for a dose effect of renin-angiotensin system inhibition on progression of microalbuminuria in Type 2 diabetes: a meta-analysis.
Blacklock CL; Hirst JA; Taylor KS; Stevens RJ; Roberts NW; Farmer AJ
Diabet Med; 2011 Oct; 28(10):1182-7. PubMed ID: 21627686
[TBL] [Abstract][Full Text] [Related]
9. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers.
Lambers Heerspink HJ; Holtkamp FA; Parving HH; Navis GJ; Lewis JB; Ritz E; de Graeff PA; de Zeeuw D
Kidney Int; 2012 Aug; 82(3):330-7. PubMed ID: 22437412
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis.
Wu HY; Huang JW; Lin HJ; Liao WC; Peng YS; Hung KY; Wu KD; Tu YK; Chien KL
BMJ; 2013 Oct; 347():f6008. PubMed ID: 24157497
[TBL] [Abstract][Full Text] [Related]
11. Maintaining Renin-Angiotensin-Aldosterone System Inhibitor Treatment with Patiromer in Hyperkalaemic Chronic Kidney Disease Patients: Comparison of a Propensity-Matched Real-World Population with AMETHYST-DN.
Chinnadurai R; Rengarajan S; Budden JJ; Quinn CM; Kalra PA
Am J Nephrol; 2023; 54(9-10):408-415. PubMed ID: 37725919
[TBL] [Abstract][Full Text] [Related]
12. Antihypertensive agents for preventing diabetic kidney disease.
Lv J; Perkovic V; Foote CV; Craig ME; Craig JC; Strippoli GF
Cochrane Database Syst Rev; 2012 Dec; 12():CD004136. PubMed ID: 23235603
[TBL] [Abstract][Full Text] [Related]
13. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
Bakris GL; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Kolkhof P; Joseph A; Pieper A; Kimmeskamp-Kirschbaum N; Ruilope LM;
JAMA; 2015 Sep; 314(9):884-94. PubMed ID: 26325557
[TBL] [Abstract][Full Text] [Related]
14. RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition.
Koszegi S; Molnar A; Lenart L; Hodrea J; Balogh DB; Lakat T; Szkibinszkij E; Hosszu A; Sparding N; Genovese F; Wagner L; Vannay A; Szabo AJ; Fekete A
J Physiol; 2019 Jan; 597(1):193-209. PubMed ID: 30324679
[TBL] [Abstract][Full Text] [Related]
15. The impact of renin-angiotensin-aldosterone system inhibitors on Type 1 and Type 2 diabetic patients with and without early diabetic nephropathy.
Hirst JA; Taylor KS; Stevens RJ; Blacklock CL; Roberts NW; Pugh CW; Farmer AJ
Kidney Int; 2012 Apr; 81(7):674-83. PubMed ID: 22189841
[TBL] [Abstract][Full Text] [Related]
16. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis.
Casas JP; Chua W; Loukogeorgakis S; Vallance P; Smeeth L; Hingorani AD; MacAllister RJ
Lancet; 2005 Dec; 366(9502):2026-33. PubMed ID: 16338452
[TBL] [Abstract][Full Text] [Related]
17. Association of statin and/or renin-angiotensin-aldosterone system modulating therapy with mortality in adults with diabetes admitted to hospital with COVID-19: A retrospective multicentre European study.
Harris S; Ruan Y; Wild SH; Wargny M; Hadjadj S; Delasalle B; Saignes M; Ryder RE; Field BCT; Narendran P; Zaccardi F; Wilmot EG; Vlacho B; Llauradó G; Mauricio D; Nagi D; Patel D; Várnai KA; Davies J; Gourdy P; Cariou B; Rea R; Khunti K;
Diabetes Metab Syndr; 2022 May; 16(5):102484. PubMed ID: 35472685
[TBL] [Abstract][Full Text] [Related]
18. Dual Blockade of the Renin-angiotensin-aldosterone System in Type 2 Diabetic Kidney Disease.
Feng YH; Fu P
Chin Med J (Engl); 2016 Jan; 129(1):81-7. PubMed ID: 26712437
[TBL] [Abstract][Full Text] [Related]
19. Effects of renin-angiotensin system blockers on renal and cardiovascular outcomes in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials.
Liu X; Ma L; Li Z
J Endocrinol Invest; 2020 Jul; 43(7):959-972. PubMed ID: 31939197
[TBL] [Abstract][Full Text] [Related]
20. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.
Ruilope LM; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Ferreira AC; Pieper A; Kimmeskamp-Kirschbaum N; Bakris GL
Am J Nephrol; 2014; 40(6):572-81. PubMed ID: 25591469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
